Lipocine
LPCN
30 hedge funds and large institutions have $8.88M invested in Lipocine in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 6 closing their positions.
60% more capital invested
Capital invested by funds: $5.56M → $8.88M (+$3.32M)
0.07% more ownership
Funds ownership: 0.68% → 0.75% (+0.07%)
6% less funds holding
Funds holding: 32 → 30 (-2)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
93% less call options, than puts
Call options by funds: $5K | Put options by funds: $76K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$366K |
| 2 |
Renaissance Technologies
New York
|
+$267K |
| 3 |
CL
Choreo LLC
Rockford,
Illinois
|
+$154K |
| 4 |
Millennium Management
New York
|
+$56.3K |
| 5 |
QCMA
Quad Capital Management Advisors
New York
|
+$47.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mercer Global Advisors
Denver,
Colorado
|
-$94.5K |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$43K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$34K |
| 4 |
SIM
Spark Investment Management
New York
|
-$34K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$22.5K |
LPCN Hedge Fund Activity: Q3 2019 in Review
30 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q3 2019, worth a combined $8.88M — up 60% from $5.56M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of LPCN and 4 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 7 added.
The largest buyer was Vanguard Group, adding an estimated $366K. The largest seller was Mercer Global Advisors, cutting an estimated $94.5K.
- 30 institutional investors held Lipocine (LPCN) as of Q3 2019, down from 32 in Q2 2019.
- Funds reported $8.88M of Lipocine stock for Q3 2019, up 60% quarter-over-quarter.
- 4 funds opened new Lipocine positions in Q3 2019 and 6 closed out, a net change of -2 holders.
- The largest Lipocine buyer in Q3 2019 was Vanguard Group, an estimated $366K added.
- The largest Lipocine seller in Q3 2019 was Mercer Global Advisors, an estimated $94.5K sold.
Based on aggregated 13F filings for Q3 2019.